-- Mr. Rhodes to serve as an advisor to Epizyme through the fourth
quarter of 2014 --
-- Mr. Rhodes will be returning to venture capital --
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company
creating innovative personalized therapeutics for patients with
genetically defined cancers, announced today that Jason Rhodes,
President and Chief Financial Officer, has resigned from the company,
effective September 30, 2014. Mr. Rhodes, who has served on Epizyme's
leadership team since 2010, will be joining a venture capital firm. The
Company has a search underway to identify a new chief financial officer,
and Mr. Rhodes has agreed to assist Epizyme in an advisory capacity
through the end of 2014 to ensure a smooth transition.
"During these past four years, Epizyme has successfully grown from a
venture-backed, research-stage company to a well-financed,
clinical-stage public company. Today, there are more than 80
extraordinary people at Epizyme pursuing our mission of creating
personalized therapeutics for patients with genetically defined cancers.
We have two ongoing clinical programs with multiple proof of concept
studies, a strong product platform and pipeline, strategic
collaborations with GSK, Celgene, Eisai, Abbott and Roche Molecular
Systems and a strong financial position with $232.1 million in cash,
cash equivalents and accounts receivable as of the end of the second
quarter of 2014", said Robert Gould, Ph.D., Chief Executive Officer.
"Jason has been instrumental in charting our strategic course and
building the business to this point. I am deeply and personally grateful
for his contributions and partnership, and everyone here at Epizyme
wishes Jason the best as he moves on to the next stage in his career."
"With world-class science and leadership, an exceptional organization
and a strong balance sheet, I believe Epizyme is well-positioned to
realize its vital mission. I have been very fortunate to have had the
opportunity to work with Robert and everyone here and am proud of
Epizyme's progress in creating innovative new therapeutics for cancer
patients and value for shareholders. I look forward to Epizyme's
continued success," said Mr. Rhodes.
About Epizyme, Inc.
Inc. is a clinical stage biopharmaceutical company creating personalized
therapeutics for patients with genetically defined cancers. Epizyme has
built a proprietary product platform that the companyuses to
create small molecule inhibitors of a 96-member class of enzymes known
as histone methyltransferases, or HMTs. HMTs are part of the system of
gene regulation, referred to as epigenetics, that controls gene
expression. Genetic alterations can result in changes to the activity of
HMTs, making them oncogenic (cancer-causing). By focusing on the genetic
drivers of cancers, Epizyme's targeted science seeks to match the right
medicines with the right patients for a personalized approach to cancer
For more information, visit www.epizyme.comand connect with us on Twitter at @EpizymeRx.
Source: Epizyme, Inc.